ReviewBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2012
Fibrotic and sclerotic manifestations of chronic graft-versus-host disease.
Review in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- A Multicenter Phase II Trial of Ruxolitinib for Treatment of Corticosteroid Refractory Sclerotic Chronic Graft-Versus-Host Disease.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Trial
- Trial
- Cutaneous Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Retrospective Cohort Study of Clinical Spectrum and Treatment Patterns.Life (Basel, Switzerland) · 2026Article
- Real-world experience of belumosudil and belumosudil/ruxolitinib combination in steroid-refractory chronic graft-versus-host disease.Bone marrow transplantation · 2025Article
- Immunological mechanisms underlying the novel application of mesenchymal stromal cell-derived extracellular vesicles (MSC-EVs) in graft-versus-host disease (GvHD) therapy.Molecular biology reports · 2025Review
- Real-world Canadian data on belumosudil therapy in heavily pretreated patients with steroid-refractory chronic graft-versus-host disease: treatment outcomes and risk factor analysis for failure-free survival.Annals of hematology · 2025Article
- Review
- A Novel Murine Model for Lupus-Like Ocular Chronic Graft-Versus-Host Disease.Investigative ophthalmology & visual science · 2024Article
- Metabolic syndrome prevalence and impact on outcomes in patients with chronic graft-versus-host disease.Bone marrow transplantation · 2023Article
- Clinical response to belumosudil in bronchiolitis obliterans syndrome: a combined analysis from 2 prospective trials.Blood advances · 2022Article
- Targeting the Retinoid X Receptor Pathway Prevents and Ameliorates Murine Chronic Graft-Versus-Host Disease.Frontiers in immunology · 2022Article
- Local Renin-Angiotensin System Activation and Myofibroblast Formation in Graft Versus Host Disease-Associated Conjunctival Fibrosis.Investigative ophthalmology & visual science · 2021Article
- Mast Cell Involvement in Fibrosis in Chronic Graft-Versus-Host Disease.International journal of molecular sciences · 2021Review
- LPSFrontiers in immunology · 2021Article
- Machine learning reveals chronic graft-Haematologica · 2019Article
- Article
- NADPH oxidase enzymes in skin fibrosis: molecular targets and therapeutic agents.Archives of dermatological research · 2014Review
- Combined meta-analysis of systemic effects of allogeneic stem cell transplantation and systemic sclerosis.BMC hematology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.